BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29278742)

  • 21. Intravenous ferrous sucrose versus placebo in addition to oral iron therapy for the treatment of severe postpartum anaemia: a randomised controlled trial.
    Perelló MF; Coloma JL; Masoller N; Esteve J; Palacio M
    BJOG; 2014 May; 121(6):706-13. PubMed ID: 24423186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
    Goldstein SL; Morris D; Warady BA
    Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats.
    Toblli JE; Cao G; Angerosa M
    Drug Des Devel Ther; 2015; 9():2585-97. PubMed ID: 26005335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous iron products.
    Johnson CA; Mason NA; Bailie GR
    ANNA J; 1999 Oct; 26(5):522-4. PubMed ID: 10776081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
    Solak Y; Atalay H; Guney I; Turkmen K; Kaya E; Turk S
    Ren Fail; 2011; 33(3):307-11. PubMed ID: 21401355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Iron Deficiency Anemia in Heart Failure.
    Saraon T; Katz SD
    Prog Cardiovasc Dis; 2016; 58(4):407-15. PubMed ID: 26657161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use of Parenteral Iron Therapy for the Treatment of Postpartum Anemia.
    Nash CM; Allen VM
    J Obstet Gynaecol Can; 2015 May; 37(5):439-442. PubMed ID: 26168105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron.
    Toblli JE; Di Gennaro F; Rivas C
    Heart Lung Circ; 2015 Jul; 24(7):686-95. PubMed ID: 25666998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative rates of adverse events with different formulations of intravenous iron.
    Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
    Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing preoperative haemoglobin with intravenous iron.
    Basora M; Colomina MJ; Tio M; Mora L; Salazar F; Ciercoles E
    Br J Anaesth; 2013 Mar; 110(3):488-90. PubMed ID: 23404979
    [No Abstract]   [Full Text] [Related]  

  • 31. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
    Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
    Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy.
    Athibovonsuk P; Manchana T; Sirisabya N
    Gynecol Oncol; 2013 Dec; 131(3):679-82. PubMed ID: 24099839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial.
    Froessler B; Cocchiaro C; Saadat-Gilani K; Hodyl N; Dekker G
    J Matern Fetal Neonatal Med; 2013 May; 26(7):654-9. PubMed ID: 23130909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
    Auerbach M; Al Talib K
    Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.
    Michael B; Fishbane S; Coyne DW; Agarwal R; Warnock DG
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):92-100. PubMed ID: 16932400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells.
    Roth S; Langguth P; Spicher K; Enzmann H
    Transl Res; 2008 Jan; 151(1):36-44. PubMed ID: 18061126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
    Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
    J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parenteral iron sucrose in iron deficiency anaemia of paediatric chronic kidney disease.
    Moorani KN; Asim S
    J Ayub Med Coll Abbottabad; 2011; 23(3):47-50. PubMed ID: 23272434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial.
    Bhavi SB; Jaju PB
    BMC Pregnancy Childbirth; 2017 May; 17(1):137. PubMed ID: 28482869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
    Tagboto S; Cropper L; Turner J; Pugh-Clarke K
    J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.